

# MINUTES

## NET ANNUAL GENERAL MEETING

**Date:** Monday 22 November 2021

**Time:** 12:30pm to 1:30pm (AEDT)

**Location:** via Zoom



AGENDA ITEM	SPOKESPERSON
<b>1. Welcome, Apologies and Conflicts of Interest</b>	<b>David Chan</b>
<p>The Chair, Dr David Chan, welcomed everyone to the meeting.</p> <p>There were 6 participants. Those in attendance were David Chan, Gabrielle Cehic, Nigel Frame, Michael Michael (in part) and Kate Wakelin. Rhonda DeSouza joined as COSA Project Manager. Apologies were received from Rod Hicks, Ankit Jain and Megan Rogers.</p> <p>No conflicts of interest were declared.</p>	
<b>2. General update re NETs Group and Executive Committee in 2021</b>	<b>David Chan</b>
<p>David thanked the NET Executive Committee (Gabrielle Cehic, Erin Laing, Michael Michael, Tim Price, Kate Wakelin and David Wyld) for their contributions and collaboration. It is wonderful to have representation from many states and disciplines on the committee.</p> <p>The major activity in 2021 has been the revision of the NET guidelines. There have been many advances in diagnosis and treatment since they were first written 10 years ago and the sections on SSAs, targeted agents and PRRT particularly needed updating. There are also new chapters on Supportive Care (diet and nutrition, psychosocial care, and exercise) and MEN1. The final drafts have been completed for all chapters and reviewed internally by the working group.</p> <p>There has unfortunately been an unforeseen delay in posting the NET guidelines to the wiki. The wiki is supported by Cancer Council Australia, however due to technical issues they are seeking to migrate existing data to a new platform. The revised NET guidelines will need to be uploaded to the new platform rather than the wiki. There are regular high level discussions between the COSA CEO (Marie Malica) and Cancer Council Australia CEO about this issue as multiple other guidelines are affected by the change. We are hopeful that the new platform will be available by Q2 2022 so that the public consultation can be completed.</p>	
<b>3. Highlights from the ASM</b>	<b>David Chan</b>
<p>The 2021 COSA ASM was held from 16-18<sup>th</sup> November as a virtual meeting. There were a few neuroendocrine presentations, including one from Aran Kanagaratnam:</p> <ul style="list-style-type: none"><li>• <u>Addition of radiosensitising chemotherapy to peptide receptor radionuclide therapy (PRRT) in neuroendocrine neoplasms (NENs): a systematic review</u></li></ul> <p>If you registered for the ASM, you have 12 months access to view the recordings of any presentations you missed or want to watch again.</p>	

<b>4. Plans for 2022</b>	<b>David Chan</b>
<p>The NET working group plans to complete the guideline project by the 2022 COSA Annual Scientific Meeting. Work will focus on the following areas:</p> <ol style="list-style-type: none"> <li>1. Upload guideline content to the new online platform when available.</li> <li>2. Conduct a public consultation and ratify the comments.</li> <li>3. Develop 2 manuscripts (one on diagnosis and the other on treatment) for publication in a peer reviewed journal (such as the <i>Journal of Neuroendocrinology</i>, as an <i>APJCO Supplement</i> or in <i>MJA</i> to capture the broader medical/surgical audience in Australia).</li> </ol>	
<b>5. Other Business</b>	<b>David Chan</b>
<p>The NET Group Terms of Reference (ToR) covers membership of the Executive Committee and appointment of the Chair. It includes the terms for committee members and the chair (initial term of 2 years, and eligible for re-appointment for a further 2 years if no objections from the Executive Committee). David and the current committee have been in office since 2019 when the NET Group was reconvened. There was overwhelming support for David to continue as Chair to ensure continuity with the guidelines project.</p> <p>The possibility of investigating radionuclide therapy-related myeloid neoplasms (e.g. myelodysplastic syndrome, leukemia) was discussed. David and others noted that PeterMac had published research in this field. AGM attendees were supportive of investigating a potential multi-state collaboration to carry this work forward. Towards the end of 2022, the group will look at succession planning and committee membership to maintain momentum.</p> <p><b>Actions:</b></p> <ul style="list-style-type: none"> <li>• <b>The NET Executive Committee will discuss the concept of looking at radionuclide therapy-related myeloid neoplasms in the COSA NETs group.</b></li> <li>• <b>The NET Executive Committee will consider inviting additional disciplines to participate.</b></li> <li>• <b>David requested attendees contact him with any other ideas for multidisciplinary, collaborative projects which fall under the auspices of COSA.</b></li> </ul>	
<b>6. Next Meeting</b>	<b>David Chan</b>
<p>The 2022 NET AGM date is to be confirmed but will likely be around the COSA ASM. Next year's conference will be held in Brisbane from 2-4 November 2022.</p> <p><b>The Chair thanked participants for their attendance and declared the meeting closed at 1.02pm.</b></p>	